TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Thursday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Trading Down 16.5 %

TherapeuticsMD stock opened at $0.86 on Thursday. The stock has a 50-day moving average price of $1.33 and a two-hundred day moving average price of $1.58. TherapeuticsMD has a 12 month low of $0.70 and a 12 month high of $2.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.